Korean Drug Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Hai Park
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | 11.4% |
| Management average tenure | no data |
| Board average tenure | no data |
Recent management updates
Recent updates
Should You Be Adding Korean Drug (KOSDAQ:014570) To Your Watchlist Today?
Mar 11
Korean Drug (KOSDAQ:014570) Is Growing Earnings But Are They A Good Guide?
Feb 19
Korean Drug Co., Ltd.'s (KOSDAQ:014570) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Feb 01Is Korean Drug Co., Ltd. (KOSDAQ:014570) Popular Amongst Insiders?
Jan 11Can You Imagine How Jubilant Korean Drug's (KOSDAQ:014570) Shareholders Feel About Its 111% Share Price Gain?
Dec 24Here's Why I Think Korean Drug (KOSDAQ:014570) Might Deserve Your Attention Today
Dec 06Are Korean Drug's (KOSDAQ:014570) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Nov 18CEO
Hai Park (88 yo)
no data
Tenure
Mr. Hai Ryong Park serves as Chairman, Chief Executive Officer and President of Korean Drug Co. Ltd. Mr. Park served as the Co-Chief Executive Officer of Korean Drug Co. Ltd., and also served as its Presid...